We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

4755:TSERakuten Group, Inc. Analysis

Data as of 2026-03-11 - not real-time

₩10,440.00

Latest Price

8/10Risk

Risk Level: High

Executive Summary

ALUX Co., Ltd. is trading at 10,440 KRW, comfortably above its 20‑day (9,394) and 50‑day (9,997) simple moving averages but still under the 200‑day average (10,543), suggesting short‑term strength within a longer‑term bearish backdrop. The MACD line sits at –140 against a signal at –208, with a positive histogram of 67 and a bullish MACD signal, while the RSI of 57 points to neutral momentum. Volume is on an upward trend, and the price sits midway between a solid support level at 8,170 KRW and resistance near 11,000 KRW, giving a clear upside target if momentum holds.
Fundamentally, the company posted a 13.9% revenue increase and a 30% gross margin, yet operating and net margins remain negative (‑3.6% and ‑8.2% respectively) with zero EPS and a sizable EBITDA loss. Cash on hand (≈49 billion KRW) exceeds debt (≈20 billion KRW), but a debt‑to‑equity ratio above 40 signals leverage concerns. Volatility is extremely high at ~90% over 30 days, beta is low (0.4), and market sentiment is in “Extreme Greed,” indicating speculative enthusiasm despite the earnings weakness.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish MACD histogram indicating short‑term momentum
  • Price trading above 20‑day and 50‑day SMAs provides technical support
  • Support at 8,170 KRW cushions downside risk

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Revenue growth of ~14% suggests top‑line expansion potential
  • Substantial cash reserves relative to debt improve financial flexibility
  • Increasing volume and extreme‑greed market sentiment support upside to 11,000 KRW

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Negative operating margins and lack of earnings raise profitability concerns
  • High debt‑to‑equity ratio could constrain future investments
  • Elevated 30‑day volatility (~90%) indicates price instability

Key Metrics & Analysis

Financial Health

Revenue Growth13.90%
Profit Margin-8.21%
Debt/Equity40.45
Op. Cash Flow₩-1388363520
Industry P/E36.8

Technical Analysis

TrendBearish
RSI57.4
Support₩8,170.00
Resistance₩11,000.00
MA 20₩9,394.00
MA 50₩9,997.40
MA 200₩10,543.25
MACDBullish
VolumeIncreasing
Fear & Greed Index75.84

Valuation

GradeFair
TypeBlend

Risk Assessment

Beta0.40
Volatility90.58%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.